Evidence map›Paper›PMID 39512425›Full record

ArticleOpen forum infectious diseases2024

Reduced Vancomycin Susceptibility in

Taryn A Eubank, Chetna Dureja, Anne J Gonzales-Luna, Julian G Hurdle, Kevin W Garey

Abstract read
In one paragraph

Article in Open forum infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Antimicrobial Susceptibility ofAntibiotics (Basel, Switzerland) · 2026
    Article
  2. Article
  3. Molecular Epidemiology ofAntibiotics (Basel, Switzerland) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Taryn A EubankDepartment of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, Texas, USA.ORCID https://orcid.org/0000-0002-6645-406X
Chetna DurejaCenter of Infectious and Inflammatory Diseases, Institute of Biosciences and Technology, Texas A&M Health Science Center, Houston, Texas, USA.ORCID https://orcid.org/0009-0001-8884-1298
Anne J Gonzales-LunaDepartment of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, Texas, USA.ORCID https://orcid.org/0000-0003-1906-359X
Julian G HurdleCenter of Infectious and Inflammatory Diseases, Institute of Biosciences and Technology, Texas A&M Health Science Center, Houston, Texas, USA.ORCID https://orcid.org/0000-0003-2214-8105
Kevin W GareyDepartment of Pharmacy Practice and Translational Research, University of Houston College of Pharmacy, Houston, Texas, USA.ORCID https://orcid.org/0000-0003-2063-7503

Funding

Diversity Supplement: Decoding the clinical impact of the recent evolution of metronidazole resistance on Clostridium difficile infectionR01AI139261 · NIAID · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI Kevin W Garey, Julian G Hurdle · 2018 to 2026
$6.0M
Texas Medical Center Training Program in Antimicrobial ResistanceT32AI141349 · NIAID · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI GARSIN, DANIELLE A · 2019 to 2023
$1.3M
NIAID NIH HHS R01 AI139261NIAID NIH HHS T32 AI141349
6 · The paper itself

Abstract

Background: Reduced vancomycin (VAN) susceptibility in clinical Methods: This multicenter cohort study included adults with Results: Five hundred and ninety-four hospitalized patients with CDI between 2016 and 2021 (female: 57%, age >65 years: 55%, White/non-Hispanic: 59%, nonsevere CDI episode: 53%) were identified. Of 594 isolates, 173 (29%) had reduced VAN susceptibility (MIC Conclusions: Certain ribotypes, including RT 027, were the sole independent risk factors for reduced VAN susceptibility. Increased clinical surveillance of these strains, especially RT 027, and their antibiotic susceptibly is warranted to inform prescribing practices.

Indexed as

anaerobesantimicrobial resistanceClostridioides difficilerisk factorsvancomycin

Identifiers

PMID39512425
PMCPMC11542623

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.